Passage Bio Narrows Q3 Loss Amid R&D Cuts, Cash Position Improves

TL;DR

Passage Bio's deep R&D cuts are stemming losses and boosting cash, but the long-term viability of its pipeline remains a massive question mark without significant new funding.

AI Summary

Passage Bio, Inc. reported a net loss of $7.7 million for the three months ended September 30, 2025, a significant improvement from the $19.3 million net loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $32.5 million, down from $52.0 million in 2024. This reduction in loss was primarily driven by a substantial decrease in research and development (R&D) expenses, which fell from $8.7 million to $4.3 million in the third quarter and from $30.6 million to $17.9 million year-to-date. General and administrative expenses also decreased, from $7.3 million to $4.3 million in the quarter. The company's cash and cash equivalents increased to $52.8 million as of September 30, 2025, from $37.6 million at December 31, 2024, largely due to $40.2 million in cash provided by investing activities, primarily from sales or maturities of marketable securities. Passage Bio effected a 1-for-20 reverse stock split on July 14, 2025, to regain compliance with Nasdaq listing requirements. The company continues to incur recurring losses and negative cash flows, with an accumulated deficit of $691.8 million, and anticipates needing substantial additional capital to fund its operations and product candidates, including its lead candidate PBFT02 for FTD-GRN.

Why It Matters

This 10-Q reveals Passage Bio's strategic shift towards cost containment, particularly in R&D, which has significantly reduced its net loss. For investors, the improved cash position to $52.8 million and the remaining $15.8 million capacity under the ATM Facility offer a short-term liquidity buffer, but the substantial accumulated deficit of $691.8 million signals ongoing capital needs. The reverse stock split, while addressing Nasdaq compliance, doesn't fundamentally alter the company's valuation or long-term prospects. Competitively, reduced R&D spending could impact the pace of development for PBFT02 and other candidates, potentially ceding ground to rivals in the neurodegenerative disease space if not managed carefully. Employees and customers will be watching for sustained progress in clinical trials, as the company's future hinges on successful product development and commercialization.

Risk Assessment

Risk Level: high — Passage Bio has an accumulated deficit of $691.8 million as of September 30, 2025, and has incurred recurring losses and negative cash flows from operations since inception. The company explicitly states that "Substantial additional capital will be needed by the Company to fund its operations and to develop its product candidates," indicating a high reliance on future financing which may not be available on acceptable terms.

Analyst Insight

Investors should monitor Passage Bio's cash burn rate closely and evaluate the impact of reduced R&D spending on its clinical pipeline, particularly PBFT02. Consider the company's ability to secure additional funding, as its current cash and ATM capacity are insufficient for long-term operations given its history of significant losses.

Financial Highlights

debt To Equity

1.38

revenue

N/A

operating Margin

N/A

total Assets

$74.2M

total Debt

$43.0M

net Income

-$7.7M

eps

-$2.44

gross Margin

N/A

cash Position

$52.8M

revenue Growth

N/A

Key Numbers

• $7.7M — Net loss for Q3 2025 (Decreased from $19.3M in Q3 2024)
• $32.5M — Net loss for nine months ended Sep 30, 2025 (Decreased from $52.0M in the same period of 2024)
• $4.3M — Research and development expenses for Q3 2025 (Decreased from $8.7M in Q3 2024)
• $17.9M — Research and development expenses for nine months ended Sep 30, 2025 (Decreased from $30.6M in the same period of 2024)
• $52.8M — Cash and cash equivalents as of Sep 30, 2025 (Increased from $37.6M at Dec 31, 2024)
• $691.8M — Accumulated deficit as of Sep 30, 2025 (Indicates significant historical losses)
• $15.8M — Remaining capacity under ATM Facility (Available for future equity sales)
• 1-for-20 — Reverse stock split ratio (Effected on July 14, 2025, to regain Nasdaq compliance)

Key Players & Entities

• Passage BIO, Inc. (company) — registrant
• Nasdaq Stock Market LLC (regulator) — exchange for common stock
• Cowen and Company, LLC (company) — sales agent for ATM Facility
• PBFT02 (company) — lead clinical product candidate
• SEC (regulator) — Securities and Exchange Commission
• FASB (regulator) — Financial Accounting Standards Board

FAQ

Risk Factors

• Substantial Accumulated Deficit [high — financial]: The company has an accumulated deficit of $691.8 million as of September 30, 2025. This indicates a history of significant losses and raises concerns about long-term financial viability without substantial future funding.
• Need for Additional Capital [high — financial]: Passage Bio anticipates needing substantial additional capital to fund its operations and product candidates. This reliance on external financing creates a risk of dilution for existing shareholders and potential funding shortfalls.
• R&D Expense Reduction [medium — operational]: R&D expenses decreased significantly to $4.3 million in Q3 2025 from $8.7 million in Q3 2024, and year-to-date expenses fell from $30.6 million to $17.9 million. While this improved net loss, it could signal a slowdown in pipeline development or a shift in strategic priorities.
• Nasdaq Compliance [medium — regulatory]: The company effected a 1-for-20 reverse stock split on July 14, 2025, to regain compliance with Nasdaq listing requirements. Continued failure to meet listing standards could result in delisting, impacting liquidity and investor confidence.

Industry Context

The gene therapy sector, where Passage Bio operates, is characterized by high R&D costs, long development timelines, and significant regulatory hurdles. Companies in this space often rely heavily on external funding due to the capital-intensive nature of drug development and the potential for substantial returns if successful.

Regulatory Implications

Passage Bio's reverse stock split highlights the ongoing pressure to maintain compliance with exchange listing requirements. Failure to do so could lead to delisting, impacting investor access and confidence. The company's reliance on future capital also implies potential scrutiny from regulatory bodies regarding its financial stability.

What Investors Should Do

1. Monitor R&D spending closely.
2. Assess the company's ability to secure future funding.
3. Evaluate the impact of the reverse stock split.
4. Review the progress of lead candidate PBFT02.

Key Dates

• 2025-09-30: End of Q3 2025 — Reported net loss of $7.7 million, improved cash position to $52.8 million, and accumulated deficit of $691.8 million.
• 2025-07-14: Reverse Stock Split — A 1-for-20 reverse stock split was executed to meet Nasdaq listing requirements, impacting share count and per-share metrics.
• 2024-09-30: End of Q3 2024 — Reported a net loss of $19.3 million, with higher R&D and G&A expenses compared to Q3 2025.
• 2024-12-31: End of Fiscal Year 2024 — Company had $37.6 million in cash and cash equivalents.

Glossary

Accumulated deficit

The total cumulative net losses of a company since its inception, minus any cumulative net income. (Indicates the company's historical profitability, with Passage Bio having a significant deficit of $691.8 million as of September 30, 2025.)

Reverse stock split

A corporate action where a company reduces the total number of its outstanding shares by consolidating existing shares into fewer, proportionally more valuable shares. (Passage Bio implemented a 1-for-20 reverse stock split on July 14, 2025, to comply with Nasdaq listing rules.)

Marketable securities

Investments that are readily convertible to cash, such as stocks, bonds, and mutual funds. (Passage Bio had $39.2 million in marketable securities at December 31, 2024, which were sold or matured, contributing $40.2 million to cash from investing activities in the nine months ended September 30, 2025.)

Operating lease liabilities

Obligations arising from lease agreements that are accounted for as operating leases, representing future rental payments. (Passage Bio has significant operating lease liabilities, totaling $43.3 million ($3.5M current, $20.8M non-current) as of September 30, 2025.)

Year-Over-Year Comparison

Passage Bio has demonstrated a significant reduction in net losses, with Q3 2025 losses at $7.7 million compared to $19.3 million in Q3 2024, and year-to-date losses at $32.5 million versus $52.0 million. This improvement is largely driven by a substantial decrease in R&D expenses, down from $8.7 million to $4.3 million in Q3 and from $30.6 million to $17.9 million year-to-date, alongside lower G&A expenses. The company's cash position has improved to $52.8 million from $37.6 million, partly due to the sale of marketable securities. However, the accumulated deficit remains substantial at $691.8 million, and the company continues to face risks related to future capital needs and Nasdaq compliance.

Key Financial Figures

• $0.0001 — t had 3,178,710 shares of common stock, $0.0001 par value per share, outstanding. Tabl

Filing Documents

• pasg-20250930x10q.htm (10-Q) — 1856KB
• pasg-20250930xex3d1.htm (EX-3.1) — 56KB
• pasg-20250930xex31d1.htm (EX-31.1) — 16KB
• pasg-20250930xex31d2.htm (EX-31.2) — 15KB
• pasg-20250930xex32d1.htm (EX-32.1) — 6KB
• pasg-20250930xex32d2.htm (EX-32.2) — 6KB
• pasg-20250930x10q001.jpg (GRAPHIC) — 53KB
• 0001104659-25-109180.txt ( ) — 7401KB
• pasg-20250930.xsd (EX-101.SCH) — 47KB
• pasg-20250930_cal.xml (EX-101.CAL) — 45KB
• pasg-20250930_def.xml (EX-101.DEF) — 174KB
• pasg-20250930_lab.xml (EX-101.LAB) — 432KB
• pasg-20250930_pre.xml (EX-101.PRE) — 319KB
• pasg-20250930x10q_htm.xml (XML) — 1171KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 27 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 42 Item 4.

Controls and Procedures

Controls and Procedures 42 PART II. OTHER INFORMATION 43 Item 1.

Legal Proceedings

Legal Proceedings 43 Item 1A.

Risk Factors

Risk Factors 43 Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities 96 Item 3. Defaults Upon Senior Securities 96 Item 4. Mine Safety Disclosures 96 Item 5. Other Information 96 Item 6. Exhibits 97

Signatures

Signatures 99 3 Table of Contents

-FINANCIAL INFORMATION

PART I-FINANCIAL INFORMATION

Interim Financial Statements

Item 1. Interim Financial Statements. Passage Bio, Inc. Balance Sheets (Unaudited) (in thousands, except share and per share data) September 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 52,773 $ 37,573 Marketable securities — 39,183 Prepaid expenses and other current assets 1,637 838 Prepaid research and development 1,320 1,221 Total current assets 55,730 78,815 Property and equipment, net 5,159 9,331 Right of use assets - operating leases 13,001 13,803 Other assets 270 463 Total assets $ 74,160 $ 102,412 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 952 $ 742 Accrued expenses and other current liabilities 4,001 6,707 Non-refundable sublicense and transition services payments 13,750 8,226 Operating lease liabilities 3,542 3,688 Total current liabilities 22,245 19,363 Operating lease liabilities - noncurrent 20,795 21,788 Total liabilities 43,040 41,151 Commitments and contingencies (note 11) Stockholders' equity: Preferred stock, $ 0.0001 par value: 10,000,000 shares authorized; no shares issued and outstanding at both September 30, 2025 and December 31, 2024 — — Common stock, $ 0.0001 par value: 300,000,000 shares authorized; 3,178,710 shares issued and outstanding at September 30, 2025 and 3,161,503 shares issued and outstanding at December 31, 2024 — — Additional paidin capital 722,894 720,488 Accumulated other comprehensive income (loss) — 8 Accumulated deficit ( 691,774 ) ( 659,235 ) Total stockholders' equity 31,120 61,261 Total liabilities and stockholders' equity $ 74,160 $ 102,412 See accompanying notes to unaudited interim financial statements. 4 Table of Contents Passage Bio, Inc. (Unaudited) Three Months Ended September 30, Nine Months Ended September 30, (in thousands, except share and per sha

View Full Filing

View this 10-Q filing on SEC EDGAR